{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Yttrium_Y-90_Clivatuzumab_Tetraxetan",
  "nciThesaurus": {
    "casRegistry": "943976-23-6",
    "chebiId": "",
    "chemicalFormula": "C16H25N5O7.Y",
    "definition": "A radioimmunoconjugate comprised of the humanized monoclonal antibody clivatuzumab, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, thereby selectively delivering a cytotoxic dose of beta radiation.",
    "fdaUniiCode": "2L271110ED",
    "identifier": "C48429",
    "preferredName": "Yttrium Y-90 Clivatuzumab Tetraxetan",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C129819",
      "C1511"
    ],
    "synonyms": [
      "90Y-hPAM4",
      "IMMU-107",
      "YTTRIUM Y-90 CLIVATUZUMAB TETRAXETAN",
      "Yttrium (90Y) Clivatuzumab Tetraxetan",
      "Yttrium Y 90 Clivatuzumab Tetraxetan",
      "Yttrium Y 90 DOTA Monoclonal Antibody HuPAM4",
      "Yttrium Y-90 Clivatuzumab Tetraxetan",
      "hPAM4-Cide",
      "hPAM4-DOTA",
      "yttrium Y 90 DOTA monoclonal antibody HuPAM4"
    ]
  }
}